Celgene expands New Jersey manufacturing centre
US-based biotechnology company Celgene has completed the first phase of a renovation at its Summit West campus in New Jersey that will house a state-of-the-art cellular immunotherapy manufacturing centre.
The 135,000ft2 facility was completed months ahead of the original plan and will enable the company to expand investigation programmes and eventually the potential commercial launch related to bb2121, its chimeric antigen receptor (CAR T) therapy being developed for certain multiple myeloma patients in conjunction with its partner bluebird bio.
RELATED ARTICLES
AlzChem plans to “significantly increase” its nitroguanidine capacity, with a new production plant that will almost double the €76 million expansion it announced in the spring.
Karsten Smet, CEO of ACI Group, looks at ways the pharmaceutical and agrochemical industries can adapt to changing times
BASF is to end production of three chemicals at its main site in Ludwigshafen. This is part of an ongoing strategic review that is being undertaken “to ensure competitiveness under changing market conditions” and will lead to about 180 job cuts.
Barentz International has acquired distributors in two different regions in short order. The acquisition of Insuqui in Paraguay followed a few weeks after that of the Anshul Life Sciences Group in India.
Price pressure stalls re-shoring in US agrochemicals, but business was brisk with positive energy at the Specialty & Agro Chemicals America event. Gregory D.L. Morris reports from Savannah
FMC Corporation has agreed to sell its Global Specialty Solutions (GSS) business to Envu for $350 million, subject to closing working capital adjustment. The deal is expected to close by year-end 2024, subject to regulatory approval and other customary closing conditions.
